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Abstract
Background: Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome has been seldom reported.
Case report: An 89-year-old female developed persistent right side chorea associated with high titers of anticardiolipin antibody (antiphospholipid antibosies
immunoglobulin (Ig)M, 45 MPL and 112 IgM aCL (MPL) after 3 months) but normal lupus anticoagulants. Her magnetic resonance imaging (MRI) showed no
abnormality, but positron emission tomography (PET) demonstrated increased bilateral striatal metabolic activity, more on the left side. Her MRI showed no cause
for chorea. The PET scan demonstrated a marked increase in the metabolic activity of the left basal ganglia.
Discussion: Her chorea remained unchanged over a 9-month follow-up period. The literature on chorea associated with high titers of antiphospholipid antibodies
in the absence of antiphospholipid syndrome is reviewed.
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Introduction
Chorea is a movement disorder characterized by involuntary,
irregular, non-stereotyped movements of the limbs, trunk, neck, and
face parts that can vary in frequency.1 Chorea can be hereditary or
non-hereditary. Among the hereditary choreas, Huntington’s disease is
the most common; other less common hereditary choreas include
chorea due to neuroacanthocytosis, Wilson’s disease, paroxysmal
choreoathetosis, spinocerebellar ataxias, McLeod syndrome, Glucose
transporter-1 deficiency syndrome (GLUT1) deficiency, dentatoru-
bropallidoluysian atrophy, Fahr’s disease, and Lesch–Nyhan syn-
drome. Non-hereditary choreas are most commonly caused by drugs
and toxins,2 followed by autoimmune disorders such as systemic lupus
erythematosus (SLE), Sjo¨gren’s syndrome, antiphospholipid antibody
syndrome (APS), Sydenham’s chorea, chorea gravidarum, vascular
and metabolic choreas,1,3,4 and paraneoplastic disorders.5
Low titers of antiphospholipid (aPL) antibodies have been reported
in 2–9% of the normal population.6,7 Higher titers can be seen in
people affected by certain viral or bacterial infections such as
mycoplasma, chlamydia, HIV, Lyme disease, and hepatitis C.8–10
Exposure to certain drugs such as hydralazine and procainamide is
another cause of increased aPL titers.11 APS is a hypercoagulable state
characterized by the presence of at least one of the following clinical
criteria of vascular thrombosis or pregnancy morbidity, in addition to
the presence of one of the following antibodies: lupus anticoagulant
(LAC or LA), anticardiolipin (aCL), or anti-b2 glycoprotein-I antibody
(ab2GPI).12 Chorea is reported in 4% of the patients with lupus
erythematosus 13,14 and can be the first manifestation of lupus in
children 15–17 or even in late-onset SLE.18 The aCL antibody is the
most frequently detected type of aPL antibodies in SLE, while LAC is
the most frequent in SLE patients with chorea.16,19 In one study of 32
lupus patients with chorea, 27 patients (84%) had LAC, 19 (52%) had
aCL, and 11 (34%) had ab2GPI.19
It is the current belief that chorea associated with aPL antibodies
occurs in the setting of fully developed APS. In recent years, however,
there have been reports of chorea in patients with high titers of aPL
antibodies in the absence of autoimmune disease or clinical APS.20,21
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In this communication, we report another patient with chorea and
high titers of aPL antibodies who does not fulfill the criteria for APS.
The literature on aPL antibody titers, pathophysiology, neuroimaging,
and treatment is also reviewed.
Case report
An 89- year-old female visited the Yale Movement Disorder clinic
on August 2014 for evaluation of involuntary movements of the right
side. She first noted subtle involuntary movements of her right hand
and right foot in May 2014. The movements gradually increased in
intensity but reached a plateau approximately 3 weeks prior to her
clinic visit. A magnetic resonance imaging scan performed within a
month after the onset of chorea showed mild bilateral microangio-
pathy in the white matter consistent with her age.
Her past medical history revealed resection of benign polyps in the
colon 11 years earlier and a resection of an early stage skin melanoma
9 years previously without recurrence. She had two miscarriages
during her youth. Her family history was negative for any neurological
disorder or any medical disorder known to cause neurological
problems. She did not drink, smoke, or use drugs.
On neurological examination she demonstrated excellent cognition
for her age. The cranial nerves were intact. Speech was normal. There
were continuous choreiform movements affecting the right upper and
lower limbs, which were more prominent distally (Video 1). The face
was spared. Subtle chorea was noted intermittently in the left foot. Her
muscle strength was 5/5 and normal. There was no hypokinesia or
rigidity. Deep tendon reflexes were 2+ and symmetrical. All modalities
of sensation were normal. There were no cerebellar findings. Her gait
was normal. An extensive blood works including assessment of hepatic
and renal functions was normal. She had a normal antinuclear
antibody and slightly increased sedimentation rate (28 mm/hour). The
aPL antibody assessment revealed abnormal values: aCL IgM: 45
MPL (normal ,12 MPL), phosphatidylserine antibody IgM of 54
MPL (normal,25 MPL), b2 glycoprotein IgM was 34 SMU (standard
IgM units) (normal ,20 SMU). LACs were absent. Repeat magnetic
resonance imaging (MRI) was unchanged from the first study. A
deoxyglucose positron emission tomography (PET) scan showed
markedly increased metabolic activity in the putamen and caudate
nuclei bilaterally, more prominent on the left side, contralateral to the
patient’s chorea (Figure 1). She was treated with aspirin 81 mg/daily.
An examination 3 months later showed no change in the pattern and
intensity of chorea. The repeat aCL IgM value was 112 and b2
glycoprotein IgM was 36.
Discussion
A review of the literature on the subject of chorea associated with a
high titer of aPL antibodies without APS (pre-APS syndrome) revealed
six previous publications: five single case reports and a small series of
10 patients (Table 1). Age of the reported patients varied from 5 to 21
years. Initial assessment of antibodies revealed an increased titer of
aCL antibodies and absent LAC in all 15 patients. The majority of the
patients, in addition to chorea, had other central nervous system
findings such as seizures, dystonia, and dementia. All patients had
normal magnetic resonance imaging. A repeat aPL antibody test
demonstrating the persistently elevated titers was documented in only
a few patients. PET was reported in one patient with unilateral chorea
and showed increased metabolic activity over the contralateral basal
ganglia. A variety of medications were tried in patients with moderate
to severe chorea (Table 1). Follow-up evaluations beyond 6 months
were reported in only three patients.
Our patient was considerably older than previously reported
patients with pre-APS syndrome, but primary APS has been reported
in elderly females with an age ranging from 65 to 79 years.14,22,23
Video 1. Choreiform movements involving both upper and lower limb,
predominantly on the right side.
Figure 1. Deoxyglucose positron emission tomography shows bilaterally increased
metabolic activity (putamen and caudate), more prominent on the left side.
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Moderately raised titers of aPL have been reported in elderly patients
with chorea and drug exposure, and immune and infectious
disorders.20 Our patient was in excellent health and did not have
history of drug exposure or infection. She did not meet the criteria for
APS due to absence of associated clinical conditions. Her miscarriages
occurred almost 60 years ago. Her repeat aPL antibodies 3 months
later showed further elevation of the titers. Her MRI showed no
findings to explain the right-sided chorea. Although Huntington’s
disease is a consideration at any age, her excellent cognition, lack of
family history and pattern of her chorea (predominantly unilateral over
a follow up period of 9 months and sparing the face and tongue) made
this diagnosis very unlikely.
At least two mechanisms have been proposed to account for the
central nervous system damage caused by aPL antibodies. The first
mechanism is that the antibodies have an affinity for the high
phospholipid content of the endothelium of the brain vessels. They
bind to the endothelium, which changes the permeability of the vessels.
This results in breakdown of the blood–brain barrier, which
contributes to hypercoagulation and thrombosis.24–26 The second
mechanism is due to aPL antibody damage to the nigro-striatal
pathway due to high binding affinity of aPL antibodies for
phospholipid-rich neurons in dopaminergic pathway. The aPL-
mediated depolarization causes dysfunction of neurons.27 Breakage
of the blood–brain barrier by aPL antibodies also makes them more
available to directly bind to neurons.
When aPL antibodies are detected but other criteria for definite
diagnosis of APS are lacking, chorea and/or other findings such as
livido reticularis, thrombocytopenia, valvular heart disease, and
nephropathy (not currently included in the definition of APS) have
been termed by some as a ‘‘Pre-APS’’ condition.20,21 Some authors
suggest that pre-APS should be treated more aggressively in order to
prevent thrombosis.21 The mechanism of chorea in pre-APS may be
different from that seen in APS. While in APS (for example APS
secondary to lupus) chorea is associated with thrombosis and elevated
titers of the LAC antibody, pre-APS (our case and those listed in the
table) is associated with an increase of aCL antibodies and a normal
titer of LAC (Table 1). Regarding antibody subtypes, IgM was the
most common subtype of aCL antibodies elevated in pre-APS patients
(including our case). This suggests that high titers of the IgM subtype of
aCL develop in pre-APS patients, and when the condition progresses
to clinical APS, an increase in the IgG subtype occurs. Hence in the
pre-APS condition, chorea is more likely the result of direct damage to
the basal ganglia by aPL antibodies than occlusion of blood vessels, the
latter being common in APS and often associated with an abnormal
MRI. On the other hand, deoxyglucose PET scan shows an increased
metabolic rate in the basal ganglia in pre-APS (our patient and that of
Sunde´n-Cullberg et al.33 in Table 1), and, hence, has higher diagnostic
value than MRI in pre-APS patients with chorea. The relation
between severity of chorea and aPL antibodies is not known. In fact,
there have been patients with prominent chorea and low levels of aPL
antibodies14 and even patients in whom aPL antibody levels remained
high even 26 months after total remission from APS symptoms.28
In APS, anticoagulants are typically used to reduce the risk of
thrombosis, and several reports have indicated a reduction or even
cessation of choreiform movements after such treatments.3,14 Since
estrogen enhances dopaminergic sensitivity and can cause chorea in
patients with APS, discontinuation of birth control pills high in
estrogen is also recommended.14 In our patient, we chose to be
conservative and treated her with aspirin 81 mg daily due to her
advanced age. She developed no further symptoms but the chorea
remained unchanged over a period of 9 months.
Although our patient’s chorea and raised level of aPL antibodies
could be coincidental, absence of other causes of chorea suggests that
chorea resulted from direct action of aCL antibodies on the neural
tissue (basal ganglia) similar to the previously reported patients with
pre-APS (Table 1). We believe our patient and the current literature
support the view that chorea can result from direct action of aCL
antibodies on neural tissue of the basal ganglia in the absence of
clinical APS. The challenge for the clinician is to decide how
aggressively to treat patients with pre-APS syndrome in order to
prevent thrombosis and other complications of APS. More data are
needed on the natural history of patients with pre-APS and the
evolution of pre-APS to APS in order to implement the best preventive
strategy.
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